Programmed death 1 (PD-1)/programmed death ligand 1 (PD-L1) inhibitors are a significant advance in the treatment of patients with nonesmall-cell lung cancer. In this study we investigated the comparative safety and efficacy of these agents when used in patients who are chemotherapy-naive vs. patients previously treated with chemotherapy. We found that PD-1/PD-L1 inhibitors have greater clinical efficacy in chemotherapy-naive patients compared with patients who were previously treated with chemotherapy. Introduction: Programmed death 1 (PD-1)/programmed death ligand 1 (PD-L1) inhibitors show significant clinical activity in nonesmall-cell lung carcinoma (NSCLC). However, there is a relative lack of data on comparative efficacy of these drugs in the first-line setting versus chemotherapy-treated patients. We compared the efficacy and toxicity of these drugs in these 2 distinct groups of patients. Materials and Methods: Electronic databases (PubMed-Medline, EMBASE, Scopus) and major conference proceedings were systematically searched for all phase I to III clinical trials in NSCLC using PD-1/PD-L1 inhibitors. Objective response rate (ORR) and progression-free survival (PFS) data were collected and combined using DerSimonian and Laird random effects model meta-analysis. The I 2 statistic was used to assess heterogeneity. Results: Seventeen distinct trials (8 with treatment-naive patients [n ¼ 937]; 14 with chemotherapy-treated patients [n ¼ 3620]; 5 with separate treatment-naive and previously treated arms) were included. Treatment-naive patients had a statistically significant higher ORR (30.2%; 95% confidence interval [CI], 22.70-38.2) than patients previously treated with chemotherapy (ORR, 20.1%; 95% CI, 17.5-22.9; P ¼ .02). No significant differences in PFS were observed between the 2 groups. Treatment-naive patients had statistically significant higher rates of all grade pneumonitis compared with previously treated patients (4.9%; 95% CI, 3.4-6.7 vs. 3.0%; 95% CI, 2.0-4.1; P ¼ .04); however, no significant differences in any other immune-related adverse events were observed. Conclusion: PD-1/PD-L1 inhibitor therapy for advanced NSCLC has a significantly higher ORR and a higher rate of immune-mediated pneumonitis when used in the first-line setting compared with chemotherapy treated patients.
Introduction
(FDA)-approved treatments for patients with advanced NSCLC who have progressed after chemotherapy. Initially, first-line treatment decisions for patients with advanced NSCLC were on the basis of the presence of genetic mutations, such as sensitizing mutations of epidermal growth factor receptor (EGFR) and translocations of anaplastic lymphoma kinase (ALK ). Unfortunately, most patients with NSCLC did not harbor these oncogenic driver mutations, and for these patients, treatment options were limited to cytotoxic chemotherapy. However in October 2016, pembrolizumab was FDA-approved in the first-line setting for patients with NSCLC, on the basis of findings from the phase III randomized KEYNOTE-024 study, which showed that single-agent pembrolizumab led to a 40% reduction in the risk of death compared with doublet chemotherapy for untreated patients with advanced disease with 50% tumor PD-L1 expression. 1 The median progression-free survival (PFS) was also improved by 4.3 months. This significant effect was observed despite that 43% of patients in the chemotherapy arm crossed over to the pembrolizumab arm. CheckMate 026 was another phase III multicenter, open-label trial, which included treatment-naive NSCLC patients with advanced disease with at least 1% of tumor PD-L1 expression and compared nivolumab with doublet chemotherapy. However this trial showed no significant advantage of nivolumab over chemotherapy; patients who received nivolumab had a median PFS of 4.2 months compared with 5.9 months for patients treated with a chemotherapy doublet chosen by the treating physician. 2 Additionally, there was no significant difference observed between the 2 arms for overall survival (OS) and objective response rate (ORR). Avelumab and durvalumab, 2 other PD-L1 inhibitors are also being evaluated in multiple clinical trials in patients with advanced NSCLC who have progressed after chemotherapy and in certain phase I trials in the first-line setting. 3, 4 Most of the trials with these agents are single-arm trials, however, they have shown efficacy in treatment-naive as well as in previously treated patients. Certain immune-related adverse events (iRAEs) were also observed with these PD-L1 inhibitors. The availability of a better-tolerated and more efficacious first-line treatment option is a practice-changing perspective for patients with NSCLC. However, because of the conflicting results observed in the first-line trials with PD-1 inhibitors we sought to determine the safety and efficacy of PD-1/PD-L1 inhibitors in advanced NSCLC in treatment-naive patients compared with patients previously treated with chemotherapy. It has been observed in trials with PD-1 inhibitors in the first-line setting as well as in chemotherapy treated patients that patients with higher PD-L1 expression even at the lowest cutoff value have higher response rates compared with patients with no PD-L1 expression. 5 Hence, to maintain uniformity only patients with positive PD-L1 expression were evaluated in our current meta-analysis.
Materials and Methods
We followed the Preferred Reporting Items for Systematic Reviews and Meta-Analyses statement to report this systematic review and meta-analysis. 6 
Data Sources and Searches
A comprehensive literature search was conducted to identify all relevant articles. The databases included PubMed-Medline, EMBASE, and Scopus. Abstracts and presentations were also reviewed from all major conference proceedings, including the American Society of Clinical Oncology and the European Society for Medical Oncology from 2010 to 2016. The dates searched were from the inception of each database to December 4, 2016. Three investigators (M.K., P.J., and S.R.) independently searched the databases. The search terms included the following keywords: PD-1, PD-L1, CD274, programmed death receptor 1, programmed death receptor ligand, immune checkpoint inhibitor, nonesmall-cell lung cancer, nivolumab, BMS936558, pembrolizumab, MK-3475, atezolizumab, MPDL3280A, avelumab, MSB0010718C, durvalumab, and MEDI-4736. The search was extended by review of references of articles included in the final selection. The search strategy for PubMed is provided in Figure 1 .
Study Selection and Data Extraction
The following predetermined inclusion criteria were used: (1) single-arm or randomized trials evaluating PD-1 and PD-L1 inhibitors as a single agent in NSCLC; (2) data available on ORR and PFS in patients with positive PD-L1 expression (defined as > 1% tumor or immune cell PD-L1 expression). Abstracts and conference proceedings from the previous 6 years were included if all relevant data were provided. Unpublished trials and letters to the editor were not eligible. Three investigators (M.K., P.J., and S.R.) independently reviewed the list of retrieved articles to choose potentially relevant articles, and disagreements about particular studies were discussed and resolved with consensus. Two reviewers (M.K. and P.J.) independently extracted data from studies using standardized data extraction sheets and all discrepancies were resolved in consensus. The following information was extracted: name of study, first author, year of publication, study design and blinding, mean age, follow-up time, line of therapy (first-line vs. subsequent therapy), study phase, study drug, PD-L1 status, ORR, PFS (in weeks), and IRAEs. The primary outcomes of interest were ORR and PFS. The secondary outcomes of interest were all IRAEs including pneumonitis, gastrointestinal side effects including diarrhea, constipation, and colitis, endocrine side effects including hypo/hyperthyroidism, adrenal toxicity, pituitary and hypothalamic side effects, increase in serum alanine transaminase, aspartate aminotransferase, and hepatitis.
Evaluation of Study Quality and Publication Bias
We used the Cochrane risk of bias assessment to explore sources of bias in included randomized trials. 7 This scale is used to evaluate the following criteria: (1) randomized sequence generation; (2) allocation concealment; (3) blinding of participants, personnel, and outcome assessors; (4) incomplete outcome data; (5) selective outcome reporting; and (6) other sources of bias. Single-arm trials have a high risk of bias by their nature, and therefore they were not further assessed for bias. For each randomized controlled trial, each item was described as low risk of bias, high risk of bias, or unclear risk of bias by 2 independent investigators (M.K. and S.R.). To examine publication bias in the results of the meta-analysis, the Egger test was used to evaluate asymmetry of the funnel plot. 
Data Synthesis and Analysis

Results
Eligible Studies
Our search retrieved 3504 publications. After excluding duplicates and screening titles of the studies, 108 articles were selected on the basis of relevance to the study topic. After abstract and full article review, 17 distinct trials were included. All studies were published in the past 5 years. We found 8 clinical trials with treatment-naive patients (n ¼ 937) and 14 clinical trials with chemotherapy treated patients (n ¼ 3620); 5 with separate treatment-naive and previously treated arms. The reasons for exclusion are listed in Figure 1 . Table 1 shows a summary of the main characteristics of the included studies and detail of the ORR, PFS, and major IRAEs of the included trials. [1] [2] [3] [4] [8] [9] [10] [11] [12] [13] [14] [15] [16] [17] [18] [19] [20] [21] [22] Each trial was identified by its unique National Clinical Trial database number. There were 6 phase I trials, 5 phase II trials, and 6 phase III trials; 11 were single-arm trials, and 6 were randomized controlled trials. The mean age of patients was 64 years, 64% of patients were male. Median duration of follow-up ranged from 17 to 168 weeks across all trials. The median duration of follow-up in the treatment-naive arm was 45 weeks (interquartile range [IQR], 34.3-51) and among the previously treated arm was 47.5 weeks (IQR, 38-56). The number of patients studied across trials ranged between 31 and 682 patients. 
Characteristics of Studies Included in Meta-Analysis
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Risk of Bias Assessment and Publication Bias
Most the studies had a high risk of selection bias, performance bias, and detection bias because most studies were open-label. All or most of the included randomized trials had a low risk of reporting bias, attrition bias, and other bias (see Supplemental Figure 1 in the online version). For studies assessing ORR in previously treated patients, no evidence of publication bias was observed in the funnel plot (see Supplemental Figure 2 in the online version). The Egger test (P ¼ .6) was not significant for publication bias.
Meta-Analyses of ORR and PFS
A meta-analysis of all 17 trials (n ¼ 4557) showed significantly higher ORR in treatment-naive patients compared with previously treated patients (ORR, 30.2%; 95% CI, 22.70-38.2 vs. ORR, 20.1%; 95% CI, 17.5-22.9, respectively; P ¼ .02; Figure 2 ). However, no significant differences in duration of PFS was observed in treatment-naive patients compared with previously treated patients (median PFS in weeks, 25.51; 95% CI, 12.97-16.68 vs. 13.96, 95% CI, 12.33-15.58, respectively; P ¼ .2; Figure 3 ).
Because of unavailability of mature survival data in treatment-naive patients, the comparison of OS was not performed. Table 2 highlights the incidence of common iRAE observed in the included trials. [1] [2] [3] [4] [8] [9] [10] [11] [12] [13] [14] [15] [16] [17] [18] [19] [20] [21] We found a significantly higher rate of pneumonitis in treatment-naive patients than in previously treated patients (4.9%, 95% CI, 3.4%-6.7% vs. 3.0%, 95% CI, 2%-4.2%; P ¼ .03; Figure 4 ). There were no significant differences in the incidences of Grade 3 and higher pneumonitis in treatment-naive and previously treated patients. No significant differences in the rates of other organ iRAEs were observed in treatment-naive patients compared with those who had been treated with chemotherapy (see Supplemental Figures 3-5 in the online version).
Incidence of iRAE Between Treatment-Naive Versus Previously Treated Patients
Discussion
In the present meta-analysis of all published clinical trials of PD-1 and PD-L1 inhibitor therapy for patients with NSCLC, we 
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Clinical Lung Cancer May 2018 -e339 observed significantly higher ORRs in treatment-naive patients who were treated with PD-1/PD-L1 inhibitors compared with patients who had received previous lines of chemotherapy. To our knowledge, this is the first meta-analysis report of differences in the efficacy and safety of PD-1/PD-L1 inhibitors in the first-line setting compared with their use as subsequent therapy in chemotherapy pretreated patients. This significant improvement is very relevant because platinum-based chemotherapy has, for decades, been the mainstay for treatment-naive patients without EGFR or ALK aberrations. Because of higher observed ORRs, our meta-analysis findings support upfront testing of all untreated patients for PD-L1 expression, and that this information should be used to design the most appropriate therapeutic plan. The availability of a more efficacious and better tolerated first-line treatment option represents an important opportunity for patients with NSCLC and a high degree of PD-L1 positivity. It has been estimated that approximately 23% to 28% of patients with advanced NSCLC have membranous PD-L1 expression on at least 50% of tumor cells.
15,16
We did not observe any significant difference in PFS in treatment-naive patients compared with those who had received chemotherapy in our meta-analysis. Our PFS analysis involved calculation of mean PFS from the median PFS values for metaanalysis. In the KEYNOTE-024 trial the upper limit of the interquartile range of the median PFS was not reached. Hence the same could not be computed as a mean and thus KEYNOTE-024 data were not included in our meta-analysis for PFS, thus undermining the power for PFS computation. Nevertheless, in some trials with PD-1/PD-L1 inhibitors discordance between PFS and OS has been observed. For instance, in the CheckMate 17, CheckMate 57, POPLAR, and OAK trials, the degree of PFS improvement was not concordant with the OS advantage in the PD-1/PD-L1 arm, suggesting a postprogression survival advantage. 8, 9, 18, 21 Post hoc analysis in 61 patients included in the POLAR study who were allowed to continue atezolizumab despite progression per Response Evaluation Criteria In Solid Tumors 1.1 showed that in 82% of these patients tumor tissue subsequently shrank or stabilized, further suggesting postprogression advantage of PD-1/PD-L1 inhibitors. 23 We used objective response as the primary end point of our analysis to ensure inclusion of a large number of patients, because mature survival data were not available for many of the recent trials and ORR is commonly accepted as a surrogate for survival outcomes in oncology.
Higher ORR has been observed in PDeL1-positive patients compared with patients with low tumor PD-L1 expression. Furthermore, all trials of PD-1/PD-L1 inhibitors in the first-line setting required tumor PD-L1 testing and only patients with positive PD-L1 expression were included in the treatment arm. Hence, to ensure uniformity we only included PDeL1-positive patients in Garon (2015) Spigel (2016) Herbst (2016) Spigel (2015) Socinski (2016) Borghaei (2015) Subtotal (I-squared = 29.7%, p = 0.171)
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Gulley (2015) Gettinger (2016) Garon (2015) First line our current analysis, in the treatment-naive as well as previously treated arms of the meta-analysis. In the CheckMate 26 trial, investigators compared nivolumab and first-line platinum-based chemotherapy in 541 patients with PD-L1 expression on 1% of tumor cells. Interestingly, the results in 423 patients with 5% PD-L1 positivity were negative in terms of PFS (hazard ratio [HR], 1.15) as well as OS (HR, 1.02). These findings suggest that patients with higher PD-L1 positivity are more likely to derive benefit from antiePD-1 therapy, but differences in the baseline characteristics of the KEYNOTE-024 and CheckMate 26 trial populations necessitate confirmation of the role of PD-L1 as a biomarker in the firstline setting.
The future for first-line treatment of NSCLC patients is rapidly evolving. To maintain uniformity across the 2 arms in our metaanalysis we excluded all trials exploring combination immunotherapy or immunotherapy with chemotherapy. However, the additional use of pembrolizumab with first-line carboplatin and pemetrexed chemotherapy was investigated in the phase II KEYNOTE-021 trial, which showed an ORR of 55% in the combination arms compared with 29% in the chemotherapy arm. 24 It is important to note that in this trial patients were enrolled independent of their tumor PD-L1 status, but those with tumor PD-L1 expression 50% had an impressive ORR of 80%. PFS was also higher in the combination arm compared with the chemotherapy only arm (HR, 0.53; P ¼ .01). Toxicity of the combination regimen was only modestly increased compared with that of chemotherapy alone. Subsequently, in May 2017 pembrolizumab in combination with carboplatin and pemetrexed chemotherapy was approved by the FDA for the treatment of patients with previously untreated, metastatic NSCLC irrespective of the PD-L1 status.
A recent study further showed that among patients who progress after treatment with PD-1/PD-L1 inhibitors compared with patients who progress after chemotherapy, those who had received checkpoint inhibitors have better response to subsequent salvage chemotherapy compared with those who did not receive immunotherapy. 25 A plausible explanation for this finding could be the activation of the immune system by checkpoint inhibition, making tumor cells more sensitive to chemotherapy. Nevertheless, this further establishes the need for assessing patients for immunotherapy early in the course of their NSCLC treatment. In our safety analysis, we observed a significantly higher rate of all grade pneumonitis in treatment-naive patients compared with chemotherapy refractory patients, however no significant differences in the incidence of other IRAEs were observed. This is an important area for further investigation because such observations highlight that the chances of developing severe IRAEs like pneumonitis might be dependent on many factors including previous therapies and patient comorbidity and large clinical trials are further needed to establish conclusive evidence.
Our current meta-analysis showing differences in the safety and efficacy of single-agent PD-1/PD-L1 inhibitors in the first-line setting compared with the chemotherapy pretreated setting has several limitations. Because of the lack of mature OS data, especially in the first-line trials, OS data could not be meta-analyzed. Further, many studies included in the meta-analysis were open-label, introducing a high chance of bias in the collection and reporting of safety outcomes like pneumonitis. However, such a bias should not be significant because the evaluation of most IRAEs (pneumonitis being an exception) was done with objective laboratory and radiological parameters and subjective adverse events were not included in the current meta-analysis. Nevertheless, the current study is, to our knowledge, the first most comprehensive effort at comparing the differential efficacy and safety profile of PD-1/PD-L1 inhibitors in first-line and previously treated NSCLC patients.
Conclusion
Our current analysis suggests that PD-1/PD-L1 inhibitors produced higher ORRs in the first-line setting compared with their use as subsequent therapy in chemotherapy pretreated patients. Of interest is our finding of a higher rate of all grade pneumonitis in treatment-naive patients, which merits further evaluation in large randomized clinical trials.
Clinical Practice Points
Programmed death 1/PD-L1 inhibitors show significant clinical activity in NSCLC. However, there is a relative lack of data on comparative efficacy and safety of these drugs in the first-line setting vs. chemotherapy-treated patients. We performed a meta-analysis of all published trials of these agents in NSCLC patients to compare the efficacy and toxicity of these drugs in these 2 distinct groups of patients. Because all first-line trials included PDeL1-positive patients, to ensure uniformity we only included PDeL1-positive patients in our current analysis, in the treatment-naive as well as previously treated arms of the meta-analysis. We observed greater efficacy in terms of higher objective response rate in treatment-naive patients compared with chemotherapy treated patients, but no differences in PFS was observed. Because of higher observed objective response rates in the firstline setting, our meta-analysis findings support upfront testing of all untreated patients for PD-L1 expression, and that this information should be used to design the most appropriate therapeutic plan. We also observed a higher rate of all-grade pneumonitis in treatment-naive patients, which merits further investigation. Disclosure V.V. discloses a consulting or advisory role for BMS, Genentech, Merck, AstraZeneca, Celgene, and Foundation Medicine. N.A.P. discloses an advisory role for AstraZeneca. The remaining authors have stated that they have no conflicts of interest.
Supplemental Data
Supplemental figures accompanying this article can be found in the online version at https://doi.org/10.1016/j.cllc.2018.01.002.
